ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.52 and traded as high as $6.65. ImmuCell shares last traded at $6.52, with a volume of 16,526 shares.
ImmuCell Trading Down 3.4%
The business's 50-day simple moving average is $6.19 and its two-hundred day simple moving average is $5.52. The company has a current ratio of 4.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $58.94 million, a PE ratio of -93.13 and a beta of 0.32.
ImmuCell (NASDAQ:ICCC - Get Free Report) last released its earnings results on Wednesday, May 14th. The biotechnology company reported $0.16 EPS for the quarter. The company had revenue of $8.07 million during the quarter. ImmuCell had a negative return on equity of 1.02% and a negative net margin of 1.00%.
Institutional Trading of ImmuCell
A number of institutional investors and hedge funds have recently modified their holdings of ICCC. Geode Capital Management LLC grew its stake in ImmuCell by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company's stock worth $332,000 after buying an additional 7,878 shares during the last quarter. Northern Trust Corp grew its position in shares of ImmuCell by 51.0% during the fourth quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 14,982 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of ImmuCell during the fourth quarter worth about $149,000. Finally, Dauntless Investment Group LLC acquired a new stake in shares of ImmuCell in the 4th quarter worth about $676,000. 13.47% of the stock is owned by institutional investors and hedge funds.
About ImmuCell
(
Get Free Report)
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ImmuCell, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuCell wasn't on the list.
While ImmuCell currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
